Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?

Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?

Angiogenesis has been regarded as essential for tumor growth and progression. Studies of many human tumors, however, suggest that their microcirculation may be provided by nonsprouting vessels and that a variety of tumors can grow and metastasize without angiogenesis. Vessel co-option, where tumor c...

Bibliografske podrobnosti
Main Authors:	Donnem, T, Hu, J, Ferguson, M, Adighibe, O, Snell, C, Harris, A, Gatter, K, Pezzella, F
Format:	Journal article
Jezik:	English
Izdano:	2013

Podobne knjige/članki

Non-angiogenic tumours and their influence on cancer biology
od: Donnem, T, et al.
Izdano: (2018)

Ways of escape: are all tumours angiogenic?
od: Pezzella, F, et al.
Izdano: (2001)

Vascular co-option in resistance to anti-angiogenic therapy
od: Domenico Ribatti, et al.
Izdano: (2023-12-01)

Why some tumours trigger neovascularisation and others don’t: the story thus far
od: Adighibe, O, et al.
Izdano: (2016)

Future options of anti-angiogenic cancer therapy
od: Yihai Cao
Izdano: (2016-02-01)

Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas.
od: Passalidou, E, et al.
Izdano: (2002)

Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas.
od: Passalidou, E, et al.
Izdano: (2002)

Is nonangiogenesis a novel pathway for cancer progression? A study using 3-dimensional tumour reconstructions.
od: Adighibe, O, et al.
Izdano: (2006)

Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases.
od: Jubb, A, et al.
Izdano: (2011)

Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases
od: Jubb, A, et al.
Izdano: (2011)

Mathematical models of anti-angiogenic therapy and vessel normalisation
od: Hutchinson, L
Izdano: (2017)

Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases
od: Gwendolyn Haas, et al.
Izdano: (2021-04-01)

Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution
od: Johannes Robert Fleischer, et al.
Izdano: (2023-01-01)

Why some tumours trigger neovascularisation and others don’t: the story thus far
od: Omanma Adighibe, et al.
Izdano: (2016-02-01)

Tumor vessel co-option: The past & the future
od: Anne Cuypers, et al.
Izdano: (2022-08-01)

Tumor angiogenesis and anti-angiogenic therapy
od: Ziheng Guo, et al.
Izdano: (2024-09-01)

Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer.
od: Hu, J, et al.
Izdano: (2005)

Tumor necrosis factor receptor-associated protein 1(TRAP1) regulates genes involved in cell cycle and metastases.
od: Liu, D, et al.
Izdano: (2010)

Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma.
od: Stewart, M, et al.
Izdano: (2002)

Generation of vessel co-option lung metastases mouse models for single-cell isolation of metastases-derived cells and endothelial cells
od: Anne Cuypers, et al.
Izdano: (2022-12-01)

Trends and Challenges in Tumor Anti-Angiogenic Therapies
od: József Jászai, et al.
Izdano: (2019-09-01)

Anti-tumor and Anti-angiogenic Ergosterols from Ganoderma lucidum
od: Shaodan Chen, et al.
Izdano: (2017-10-01)

Tumor vessel co-option probed by single-cell analysis
od: Laure-Anne Teuwen, et al.
Izdano: (2021-06-01)

JMY protein, a regulator of P53 and cytoplasmic actin filaments, is expressed in normal and neoplastic tissues.
od: Adighibe, O, et al.
Izdano: (2014)

Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas.
od: Sivridis, E, et al.
Izdano: (2002)

Anti-Tumoral and Anti-Angiogenic Effects of Low-Diluted Phenacetinum on Melanoma
od: Camille Fuselier, et al.
Izdano: (2021-03-01)

Vascular Co-Option and Other Alternative Modalities of Growth of Tumor Vasculature in Glioblastoma
od: Domenico Ribatti, et al.
Izdano: (2022-03-01)

Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.
od: Giatromanolaki, A, et al.
Izdano: (2001)

Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation
od: Chao-Nan Qian, et al.
Izdano: (2016-01-01)

Angiogenic signaling pathways and anti-angiogenic therapy for cancer
od: Zhen-Ling Liu, et al.
Izdano: (2023-05-01)

Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy
od: Lars M. Schiffmann, et al.
Izdano: (2022-05-01)

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors
od: Tian Yufeng, et al.
Izdano: (2010-06-01)

The distribution of lymphatic vessels in lymphomas compared with reactive lymphadenopathy.
od: Pillai, G, et al.
Izdano: (2003)

Differential action of pro-angiogenic and anti-angiogenic components of Danhong injection in ischemic vascular disease or tumor models
od: Shuang He, et al.
Izdano: (2022-01-01)

Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases
od: Dipti Vijayan, et al.
Izdano: (2017-05-01)

Bone metastases from renal cell carcinoma: 4 years after aggressive surgeries and anti‐angiogenic therapy
od: Mouadh Nefiss, et al.
Izdano: (2022-11-01)

The angiogenic receptor KDR is widely distributed in human tissues and tumours and relocates intracellularly on phosphorylation. An immunohistochemical study.
od: Stewart, M, et al.
Izdano: (2003)

Editorial for the Special Issue “Angiogenic Growth Factors in Tumor Development: Beyond New Blood Vessels Formation”
od: Camilla Palumbo, et al.
Izdano: (2024-11-01)

Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases
od: Miran Rada, et al.
Izdano: (2021-08-01)

Neuroendocrine tumors with hepatic metastases: A review of evolving treatment options
od: Steven D. Colquhoun
Izdano: (2018-06-01)